University of Michigan spin-off NanoBio Corporation has received its second grant for vaccine development from the Bill and Melinda Gates Foundation. The new $6 million grant is for development of an intranasal vaccine for respiratory syncytial virus (RSV). No approved RSV vaccines are available currently. In 2005, prior to the spin off from UM, the company received $6.3 million from the Gates Foundation for intranasal vaccine development. Read the company’s press release.
Gates Foundation awards $6 million grant to NanoBio for intranasal RSV vaccine
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
